TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES

摘要: FIELD: medicine.SUBSTANCE: group of inventions refers to cancer immunotherapy, particularly pancreatic duct adenocarcinoma (PDAC). What is presented are agents and methods treating a population patients suffering PDAC tumors expressing wild-type KRAS protein. Embodiments the invention include administering nimotuzumab patient with having sequence, corresponding SEQ ID NO: 7 or 24, does not contain mutation in amino acid residue codon G12. Method may involve addition other anticancer agents. Also disclosed method predicting immunity PDAC, based on presence tumor; wherein G12 24 indicates that said will be non-responsive treatment.EFFECT: enables increasing survival rate patients.23 cl, 4 dwg, 1 tbl, 2 ex